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Epidemiology, University of Lübeck, Lübeck, Germany, 6 Hamburg Cancer Registry, Ministry for Health and Consumer Protection, Hamburg, Germany, 7 Cancer Registry of
Bremen, Leibniz-Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
Abstract
Risk of colorectal cancer (CRC) is considerably higher in men compared to women; however, there is inconclusive evidence
of sex differences in CRC prognosis. We aimed to assess and explain sex differences in 5-year relative survival using standard
and model-based period analysis among 164,996 patients diagnosed with CRC from 1997 to 2006 and reported to 11
German cancer registries covering a population of 33 million inhabitants. Age-adjusted 5-year relative survival was higher in
women (64.5% vs. 61.9%, P,0.0001). A substantial survival advantage of women was confirmed in multivariate analysis after
adjusting for CRC stage and subsite in subjects under 65 years of age (relative excess risk, RER 0.86, 95% CI 0.82–0.90), but
not in older subjects (RER 1.01, 95% CI 0.98–1.04); this pattern was similar in the 1st and in the 2nd to 5th year after
diagnosis. The survival advantage of women varied by CRC stage and age and was most pronounced for localized disease
(RERs 0.59–0.88 in various age subgroups) and in patients under 45 years of age (RERs 0.59, 0.72 and 0.76 in patients with
localized, regional or advanced disease, respectively). On the contrary, sex differences in survival did not vary by location of
CRC. In conclusion, our large population-based study confirmed a survival advantage of female compared to male CRC
patients, most notably in young and middle aged patients and patients with localized disease. The effect of sex hormones,
either endogenous or through hormonal replacement therapy, might be the most plausible explanation for the observed
patterns.
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Introduction
Colorectal cancer (CRC) is the third most common cancer and
the fourth most common cancer cause of death, accounting for
more than 600,000 deaths per year globally [1]. In most countries,
incidence and mortality rates are considerably higher in men than
in women [2]. On the other hand, findings regarding sex
differences in prognosis have been less consistent. Several studies
reported superior survival in females [3,4,5]; however, other
studies did not report any difference [6].
Two recent studies examined potential variation of sex
differences in survival of CRC patients by age. Whereas younger
women exhibited better survival than younger men, an opposite
pattern was seen among older patients [7,8]. As the age cut off
(around 50 years) was chosen as a surrogate for natural
menopause, it was hypothesized that the survival advantage of
female patients at younger age could be partially explained by
favourable effect of endogenous female sex hormones.
Other factors potentially accounting for sex differences in
survival are differences in use of screening offers and stage at
diagnosis, and differences in site distribution of CRC. Offer and
use of screening examinations vary between countries [9]. In
Germany, screening by faecal occult blood test (FOBT) has been
offered since 1977. Since 2002, colonoscopy has been offered as
primary screening examination from age 55 on. Participation rates
have been higher in women than in men for both FOBT and
screening colonoscopy, especially in younger age groups, which
may have contributed to a higher proportion of early stages and
better prognosis [10,11]. As a different mediator of survival
advantage in women, higher postoperative morbidity in men
leading to early deaths unrelated to CRC was hypothesized [12].
On the other hand, CRC is more often located in the proximal
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colon among women [13]; this was reported to be a rather
unfavourable prognostic factor [14,15].
We aimed to compare survival from CRC between men and
women and to explore potential reasons for sex differences in a
large population-based cancer survival study from Germany.
Materials and Methods
Sources of Data
As this was a retrospective epidemiological study based on
anonymised cancer registry data, neither approval of the ethics
committee nor patient informed consent was needed.
This analysis is part of a collaborative project aiming for
comprehensive monitoring of cancer survival in Germany. Full
details were described elsewhere [16]. In brief, German cancer
registries from 13 of 16 federal states submitted data for the study.
Only areas with estimated completeness of cancer registration over
80% in the period 2004–2006 and reasonably low proportions of
death certificate only (DCO) cases (under 20% throughout the
study period or constantly decreasing to levels below 20% at the
end of study period) were considered for the analysis. Subsequent-
ly, only data of selected districts from four states were included in
the analyses. We eventually utilized data from 11 cancer registries
covering a population of 33 million inhabitants.
The database for this analysis included patients with a primary
invasive CRC (ICD-10 C18–C20) at the age of 15 years or older in
1997–2006. We excluded cases notified by DCO. For the stage-
specific analysis, stage grouping according to ENCR recommen-
dations (localized, regional, and advanced cancer) was used [17].
Tumour site and morphology of tumours were coded according
to ICD-O-3 [18]. Right colon included caecum (topography code
C18.0), ascending colon (C18.2), hepatic flexure (C18.3), and
transverse colon (C18.4). Left colon included splenic flexure
(C18.5), descending (C18.6) and sigmoid (C18.7) colon. Cancers of
appendix, overlapping lesions and cancers within unspecified
colonic subsite were included in the ‘Colon – unspecified/other’
group. For the purpose of our analysis, rectosigmoid junction
(C19) and rectum (C20) were considered together.
Statistical Methods
To quantify excess mortality due to cancer, relative survival is
commonly computed in population based cancer survival studies.
It is derived as the ratio of the observed survival of cancer patients
and the expected survival of the underlying general population
[19]. In our analysis, expected survival was estimated by the so-
called Ederer II method [20] using life tables stratified by age, sex,
calendar period and federal state as obtained from participating
cancer registries and the German Federal Statistical Office. To
allow for comparisons between subgroups or populations with
potentially different age distribution, age adjustment was done
using the International Cancer Survival Standards proposed by
Corazziari et al. [21]. Period analysis [22] was employed to
provide the most up-to-date estimates of 5-year relative survival.
The period analysis included survival experience in the period
from 2002 to 2006; all observations were left truncated at the
beginning of 2002 and right censored at the end of 2006.
Extensive empirical evaluations have shown that period analysis
provides 5-year survival estimates that are very close to 5-year
survival later observed for the patients diagnosed within the period
of investigation [23,24] and is now widely used in cancer registry
based survival analyses (e.g. [25,26,27]). To evaluate the
contribution of early postoperative mortality and later mortality
to sex differences, 1-year relative mortality as well as relative
survival at 5 years after diagnosis conditional on surviving 1 year
was calculated in addition to overall 5-year relative survival.
Standard errors were estimated using Greenwood’s formula, sex
differences were tested for statistical significance by model-based
period analysis [28].
Model-based period analysis was also used to perform
multivariate analysis [29]. Briefly, numbers of deaths were
modelled as a function of the categorical variables year of follow
up, age (15–44, 45–54, 55–64, 65–74, 75+), sex, CRC stage
(localized, regional, advanced, not reported) and subsite (left colon,
right colon, colon – unspecified/other, rectum) with the logarithm
of the person-years at risk as an offset. Estimates of relative excess
risk (RER) of dying from CRC (women vs. men) and a P-value for
the difference in excess risks between sexes were derived using
described statistical model with different interaction terms
included among covariates. To assess potential effect of age on
sex differences, we first included an interaction term of sex and
age. To assess whether women’s advantage differ between
subgroups by stage or subsite, we fitted models moreover including
interactions of sex and stage or sex and subsite. To estimate the
log(RER) for a particular age-stage subgroup, we calculated the
sum of following terms: the regression coefficient for the effect of
female sex, the respective regression coefficient for the interaction
of female sex and particular age group, and the respective
regression coefficient for the interaction of female sex and
particular stage. An analogous procedure was applied to estimate
the log(RER) for a particular age-subsite subgroup.
All calculations were carried out by SAS software version 9.3
(SAS Institute, Cary, NC), using a publicly available macro for
period analysis [30] and its adaptation for modelled period
analysis [28] and multivariate analysis.
Results
After exclusion of 27,076 DCO notifications (14.1%), records of
164,996 CRC patients from 11 German cancer registries were
retained for analysis. The vast majority of cancers (97.8%) were
microscopically verified.
Table 1 shows distributions of male and female patients
according to age and CRC stage and subsite. Slightly more men
(86,704) than women (78,292) were diagnosed with CRC in 1997–
2006. Women were diagnosed at later age (median age 73 years vs.
68 years for males) and subsequently have a higher proportion of
DCO cases than men (16.3% vs. 11.8%, data not shown) and also
a higher proportion of cases with unknown stage (43.5% vs.
41.0%). Stage was reported for 95,422 cancer patients, of whom
44.2%, 27.7%, and 28.1% were diagnosed in localized, regional,
and advanced stage. Proportions of localized, regional and
advanced cancers among those with known stage were similar in
men (44.5%, 27.0% and 28.5%) and women (44.0%, 28.5% and
27.6%). On the other hand, right colon tumours were more
common in females (30.8% of CRCs in women vs. 22.5% in men)
and rectal tumours were more common in males (40.3% of CRCs
in men vs. 32.5% in women).
As shown in Table 2, age-adjusted 5-year relative survival was
higher in women (64.5% vs. 61.9%, P-value,0.0001). Age-specific
5-year relative survival decreased with increasing age in both men
(65.5% in youngest to 54.8% in oldest) and women (71.8% in
youngest to 56.7% in oldest). The survival advantage of women
was largest in patients below 45 years of age (6.3 percent units) and
between 50 and 64 years of age (between 3.8 and 6.0 percent
units).
Table 3 shows age-specific sex differences in relative survival,
considering separately risk of death in first year after diagnosis and
in the following 4 years. Relative survival decreased with age
Sex Differences in Colorectal Cancer Survival
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during the first year after diagnosis (89.0% to 75.9% in men,
92.1% to 74.6% in women). By contrast, the 5-year relative
survival conditional on surviving one year was very similar across
age groups. Except for the oldest age group, relative survival was
higher in women both during the first year (significant in patients
aged 15–74) and during 2nd to 5th year (significant in age groups
15–44 and 55–64).
We further used model-based period analysis to summarize sex
differences in relative survival providing relative excess risk (RER)
of dying from CRC (women vs. men). A substantial survival
advantage of women was observed among subjects under 65 years
of age (RER 0.84, 95% CI 0.80–0.87), but not in older subjects
(RER 0.98, 95% CI 0.95–1.01). To evaluate the contribution of
potential stage and subsite distribution differences between sexes,
we added these variables in the multivariate model. Age-specific
results were practically unchanged by the adjustment for both
younger (RER 0.86, 95% CI 0.82–0.90) and older subjects (RER
1.01, 95% CI 0.98–1.04). Findings were similar when we excluded
the first year of follow-up from the analyses and considered only
excess mortality in the 2nd to 5th year. Resulting RERs were 0.91
(95% CI 0.86–0.96) in younger and 1.02 (95% CI 0.97–1.07) in
older subjects.
Table 4 shows sex differences in 5-year relative survival in
subgroups by age and stage (model results in Table S1). The
prognosis was substantially better in patients with early disease and
was worsening with increasing age in both sexes. Relative survival
of patients with localized disease was consistently higher in
women, regardless of age. When looking at patients with regional
or advanced disease, women had a survival advantage only under
65 years of age (borderline significant or nonsignificant in patients
aged 45–54 years). With sex differences of 3.3, 2.0 and 8.4 percent
units and RERs of 0.59, 0.72, and 0.76, the survival advantage of
women was most pronounced in patients below 45 years of age
with localized, regional or advanced disease, respectively. By
contrast, worse survival was noted for women among patients with
advanced disease aged over 75 years (RER 1.13, P-value,0.0001).
Table 1. Sex differences in distributions of age, stage and
subsite in colorectal cancer patients diagnosed between 1997
and 2006.
Men Women
N %* N %*
Age
15–44 2,159 2.5 1,954 2.5
45–49 2,395 2.8 1,812 2.3
50–54 4,378 5.0 3,014 3.8
55–59 7,857 9.1 4,903 6.3
60–64 13,925 16.1 8,297 10.6
65–69 17,034 19.6 10,707 13.7
70–74 15,726 18.1 12,117 15.5
75–79 12,382 14.3 14,267 18.2
80–84 7,043 8.1 11,930 15.2
85+ 3,805 4.4 9,291 11.9
Stage
Localized 22,773 26.3 19,451 24.8
Regional 13,832 16.0 12,593 16.1
Advanced 14,573 16.8 12,200 15.6
Not reported 35,526 41.0 34,048 43.5
Subsite
Right colon 19,520 22.5 24,094 30.8
Left colon 25,393 29.3 21,703 27.7
Colon-unspecified/other 6,821 7.9 7,084 9.0
Rectum 34,970 40.3 25,411 32.5
Total 86,704 78,292
*Percentages represent proportion of all males/females.
doi:10.1371/journal.pone.0068077.t001
Table 2. Age-specific 5-year relative survival of colorectal




Age RS, % SE RS, % SE Difference P-value
15–44 65.5 1.5 71.8 1.5 6.3 ,0.001
45–49 66.0 1.4 65.6 1.6 20.4 0.95
50–54 62.8 1.1 68.2 1.3 5.4 ,0.001
55–59 64.9 0.8 68.7 1.0 3.8 ,0.001
60–64 64.1 0.6 70.2 0.8 6.0 ,0.0001
65–69 64.4 0.6 65.6 0.7 1.2 0.05
70–74 61.6 0.7 63.2 0.7 1.6 0.04
75–79 59.2 0.9 59.5 0.7 0.4 0.63
80–84 54.5 1.5 57.2 1.0 2.8 0.49
85+ 54.8 2.7 56.7 1.6 1.9 0.35
Overall* 61.9 0.3 64.5 0.3 2.6 ,0.0001
RS: relative survival point estimate, SE: standard error of the estimate.
*Age-adjusted relative survival, testing performed using age-adjusted model.
doi:10.1371/journal.pone.0068077.t002
Table 3. Age-specific 1-year relative survival and 5-year





Age RS, % SE RS, % SE Difference
P-
value
1-year 15–44 89.0 0.8 92.1 0.8 3.1 ,0.01
relative
survival
45–54 88.6 0.5 91.0 0.5 2.4 ,0.01
55–64 88.3 0.3 90.8 0.3 2.5 ,0.0001
65–74 85.3 0.3 86.7 0.3 1.4 ,0.001
75+ 75.9 0.4 74.6 0.3 21.3 0.02
2nd to 5th
year
15–44 73.7 1.5 78.0 1.4 4.3 0.01
conditional
survival
45–54 72.1 0.9 73.9 1.0 1.8 0.29
55–64 72.9 0.5 76.7 0.6 3.8 ,0.0001
65–74 73.9 0.5 74.3 0.5 0.4 0.74
75+ 75.1 0.9 77.2 0.7 2.1 0.35
RS: relative survival point estimate, SE: standard error of the estimate.
doi:10.1371/journal.pone.0068077.t003
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Results of patients with unreported CRC stage show similar sex
differences as those for staged patients.
Sex differences in 5-year relative survival in subgroups by age
and subsite are shown in Table 5 (model results in Table S2).
Again, most of relative survival estimates were higher in women,
with the exception of left colon and rectum cancer patients aged
over 75 years. The multivariate model showed similar patterns of
age-specific survival advantages for female patients across CRC
subsites, suggesting independence of disease localization of survival
advantages of women (P-value for interaction term 0.12).
Discussion
To our knowledge, this is to date the largest study specifically
focusing on sex differences in CRC survival and the first one
utilizing multivariate population-based relative survival analysis
including CRC stage and disease subsite. We found an overall
survival advantage of female CRC patients compared to male
patients. The difference in 5-year relative survival was most
pronounced in patients under 65 years of age, with the exception
of patients aged 45–49 years. Excess risk of death was 14% lower
in young (under 65 years of age) women compared to men even
after adjustments for stage and subsite. Lower excess risk of CRC
death was not limited to the first year after diagnosis, but persisted
also during subsequent years. Among patients with localized
disease, a survival advantage of women was seen at all ages. By
contrast, the survival advantage of women was confined to patients
below 65 years of age when the diagnosis was made at a regional
or advanced stage. Among patients with advanced stage CRC,
older women ($75 years) had significantly worse prognosis than
men. Sex differences in survival did not vary by location of CRC.
Previous evidence on importance of sex as a CRC prognostic
factor has been inconclusive. Two hospital-based studies reported
higher disease-specific survival following colorectal surgery in
women [4,5]. The EUROCARE-4 study, which reported 5-year
relative survival of cancer patients in European countries
diagnosed between 1995 and 1999, found higher survival in
women in most sites, including colon and rectum. However, no
comparison was provided adjusting for strong prognostic factors,
such as CRC stage and subsite [31]. Studies examining patients
diagnosed in the 1980s or earlier, including a EUROCARE high
resolution study on 5-year relative survival [32], mostly had not
shown any differences in survival between sexes [6], and it was
suggested that the differences were actually arising and widening
in recent years [7]. Recent population-based studies observed
higher cancer-specific survival in younger (i.e. individuals aged
below 45 [7] or 50 [8] years) women compared to men, but equal
or worse survival in older women compared to men. In our study,
the survival advantage of female patients was still substantial
among individuals aged 60–64.
We have found substantial differences between subgroups by
CRC stage in older patients. Whereas survival in patients with
localised cancers was higher in women, survival from metastatic
CRC was higher in men. Worse cancer-specific survival in women
compared to men was previously noted among older patients in an
Australian study; however, no interaction between sex and clinical
stage was found [8]. Other studies reported better survival for
females and also addressed a possible modifying effect of stage.
Table 4. Sex differences in 5-year relative survival of colorectal patients for subgroups by stage and age.
Men Women Women-Men Multivariate model
Stage Age RS, % SE RS, % SE Difference RER, 95% CI P-value
Localized 15–44 90.7 1.9 94.0 1.6 3.3 0.59 (0.49–0.72) ,0.0001
45–54 90.3 1.2 92.4 1.2 2.1 0.73 (0.63–0.85) ,0.0001
55–64 90.9 0.7 92.6 0.8 1.7 0.72 (0.64–0.82) ,0.0001
65–74 88.3 0.8 88.5 0.8 0.1 0.81 (0.72–0.92) ,0.01
75+ 83.3 1.6 90.2 1.2 6.9 0.88 (0.78–1.00) 0.05
Regional 15–44 71.7 3.3 73.7 3.3 2.0 0.72 (0.61–0.85) ,0.0001
45–54 68.1 1.9 71.0 2.3 2.9 0.90 (0.80–1.00) 0.05
55–64 66.6 1.2 72.3 1.4 5.7 0.88 (0.81–0.96) ,0.01
65–74 66.7 1.2 63.8 1.2 22.8 0.99 (0.92–1.07) 0.88
75+ 61.0 2.0 58.2 1.5 22.8 1.08 (1.00–1.16) 0.06
Advanced 15–44 19.6 2.8 28.0 3.2 8.4 0.76 (0.65–0.88) ,0.001
45–54 18.3 1.5 20.4 1.9 2.1 0.94 (0.86–1.03) 0.18
55–64 16.5 0.9 18.4 1.3 1.9 0.93 (0.87–0.98) 0.01
65–74 14.8 0.8 13.1 0.9 21.8 1.04 (0.99–1.10) 0.11
75+ 10.1 1.1 9.5 0.8 20.5 1.13 (1.07–1.18) ,0.0001
Not reported 15–44 72.4 2.5 83.6 2.1 11.2 0.66 (0.56–0.77) ,0.0001
45–54 71.3 1.5 76.4 1.6 5.1 0.82 (0.74–0.90) ,0.0001
55–64 68.3 0.8 73.4 1.0 5.1 0.81 (0.76–0.86) ,0.0001
65–74 62.9 0.8 68.1 0.8 5.2 0.91 (0.86–0.95) ,0.001
75+ 56.0 1.1 55.5 0.8 20.5 0.98 (0.93–1.03) 0.42
RS: relative survival point estimate, SE: standard error of the estimate, RER: relative excess risk women vs. men, CI: confidence interval.
*adjusting for age, stage and subsite, including interaction of sex with age and sex with stage.
Estimates of relative excess risk (RER) associated with female sex were derived using multivariate model*.
doi:10.1371/journal.pone.0068077.t004
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The results are, however, conflicting. One of these studies did not
find variation of sex differences by stage [3]. Other studies
reported higher survival in female patients for CRC stage I or IV
only [5], or for stage II only [12].
Female sex hormones decrease the risk of CRC, and
postmenopausal women have increased risk of colon cancer
compared to premenopausal women of the same age [33]. This
effect is not limited to endogenous hormones, as use of oral
contraceptives [34] and postmenopausal hormonal replacement
therapy (HRT) seem to also protect women from CRC. Women
using HRT were shown to be at lower risk of CRC in a meta-
analysis of 18 epidemiologic studies [35] and in a randomized trial
[36]. Most notably, HRT use was also shown to extend survival in
CRC patients [37,38,39].
A protective effect of endogenous female sex hormones may
explain the superior survival of young women compared to men.
Surprisingly, we did not find higher survival in female patients 45–
49 compared to males. According to a national German survey
performed in 2003, this was the age group when most of women
started HRT [40]. A possible explanation for the survival patterns
observed in our study might be that lower oestrogen exposition in
perimenopausal period before inception of HRT might have
accounted for the weak survival advantage of women aged 45–49;
more frequent use in older women might have contributed to the
stronger survival benefit of older postmenopausal women. Three
other German surveys performed between 1997 and 2003 [41]
showed that current HRT use sharply dropped after 65 years of
age, which corresponds well with sex differences patterns observed
in our study.
Higher survival of women with early CRC has previously been
noted in a study examining a cohort of patients after colorectal
surgery. It has been hypothesized that influences of sex hormones
on the immune system may be the reason for observed differences,
as testosterone has a detrimental effect, and female hormones have
stimulatory effects on immunological response [5]. The observed
patterns are consistent with this immunological hypothesis, as
patients with early CRC don’t regularly undergo adjuvant
treatment and their immunological barrier is thought to be
usually sufficient to cope with cancer spread [5]. Paulson and
colleagues indeed showed that the survival advantage of women is
limited to patients without adjuvant therapy [3]. Lower survival
may also be associated with an ongoing inflammatory response,
with elevated C-reactive protein, which is seen more often in males
[42] and which reflect an increased number of deaths from
cardiovascular diseases mainly in men [4,43]. Oestrogen further-
more seems to play role in protection of female cancer patients
against cardiac mass loss [44].
To answer the question, whether higher survival of women
could be partially explained by use of screening offers by
individuals over 50 (likely reflected in CRC stage distribution),
and differences in subsite distribution of CRC, we fitted a further
multivariate model and adjusted for potentially different propor-
tions of early or left-sided tumours. However, estimates of relative
excess risk barely changed when we included these variables in our
multivariate model, suggesting an at best very modest contribution
to the higher survival in young women. Early post-operative
mortality also seems to explain only a small part of the advantage.
Our modelling results rather point to long-term decreased excess
risk of death in younger and middle-aged women, possibly due to
sustained protective effects of female sex hormones.
Most studies assessing the difference between men and women
in CRC survival estimated either overall or cancer-specific
survival. Overall survival considers deaths from all causes and is
therefore affected by comorbidities, which may considerably differ
between men and women. This estimate is therefore usually
accompanied by cancer-specific survival; however, inaccurate
classification of the cause of death may still confound the results
[6]. In our study, we assessed relative survival, which is the
preferred and most widely used measure of cancer outcomes in
population-based registries. It provides information on the excess
Table 5. Sex differences in 5-year relative survival of colorectal patients for subgroups by subsite and age.
Men Women Women-Men Multivariate model
Subsite Age RS, % SE RS, % SE Difference RER, 95% CI P-value
Right colon 15–44 64.9 3.1 68.1 3.1 3.1 0.70 (0.59–0.82) ,0.0001
45–54 61.7 2.0 64.1 2.2 2.4 0.86 (0.78–0.95) ,0.01
55–64 62.1 1.2 65.7 1.3 3.6 0.84 (0.79–0.91) ,0.0001
65–74 63.7 1.0 64.3 0.9 0.6 0.94 (0.88–0.99) 0.03
75+ 61.5 1.4 64.3 0.9 2.8 1.01 (0.95–1.06) 0.82
Left colon 15–44 63.5 3.1 70.2 2.7 6.7 0.75 (0.63–0.88) ,0.001
45–54 65.4 1.7 67.9 1.8 2.6 0.92 (0.83–1.02) 0.11
55–64 69.7 0.9 71.9 1.1 2.1 0.90 (0.84–0.97) ,0.01
65–74 65.9 0.8 67.1 0.9 1.2 1.00 (0.94–1.06) 0.97
75+ 58.9 1.4 58.6 1.1 20.3 1.08 (1.02–1.14) 0.01
Rectum 15–44 65.4 2.3 72.5 2.6 7.1 0.73 (0.62–0.86) ,0.001
45–54 64.8 1.2 68.8 1.6 3.9 0.90 (0.82–0.99) 0.03
55–64 63.0 0.8 71.7 0.9 8.7 0.88 (0.83–0.94) ,0.0001
65–74 62.0 0.8 63.8 0.9 1.8 0.98 (0.93–1.03) 0.40
75+ 53.1 1.3 51.4 1.0 21.7 1.05 (0.99–1.11) 0.08
RS: relative survival point estimate, SE: standard error of the estimate, RER: relative excess risk women vs. men, CI: confidence interval.
*adjusting for age, stage and subsite, including interaction of sex with age and sex with subsite.
Estimates of relative excess risk (RER) associated with female sex were derived using multivariate model* (‘Colon - unspecified/other’ subsite cases were omitted).
doi:10.1371/journal.pone.0068077.t005
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mortality associated with CRC irrespective whether it is directly or
indirectly related to the disease. Relative survival has the
advantage to be independent of recorded cause of death, and it
also takes deaths from cardiovascular events possibly associated
with CRC diagnosis or treatment into account.
A major limitation of our study is the lack of specific indicators
of hormonal status, such as information on menopausal status,
HRT or use of oral contraceptives which prohibited a more direct
assessment of their impact. However, this limitation is shared with
most registry based studies. Similarly, we were not able to include
information on a given CRC treatment, which is usually not
available in population-based registries [45]. There was a
substantial proportion of cases without complete information on
CRC stage. Nevertheless, we were still able to include almost
100,000 patients with recorded CRC stage from different German
federal states in the multivariate analysis. Furthermore, lack of
stage information is mostly due to registry practice, and unlikely to
be a source of selection bias resulting from differential registration
practices for men and women. This assumption is supported by
the similarity of age specific sex differences in staged and unstaged
patients.
In conclusion, our large population-based study confirmed a
CRC survival advantage of women compared to men in Germany.
Higher female 5-year age-adjusted relative survival compared to
men was most pronounced in young and middle aged patients and
patients with localized disease. Differences in survival between
sexes were not restricted to early postoperative mortality, and they
were not explained by different distribution of CRC stages or
subsites. Taken together, our results support the hypothesis that
sex hormones might be a plausible explanation of better CRC
prognosis among young female patients. In our study, women
aged 50–64 also had higher relative survival than male patients of
the same age, which might be explained by notable exposure of
German women to HRT during the study period. Efforts should
be made to further elucidate the reasons underlying the survival
advantages of women among CRC patients and their potential
implications for clinical practice.
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